Initial Order of Biofield Devices and Sensors Delivered to New Filipino Joint Venture for Major Breast Cancer Symposium to Take Place in Manila on October 24.

PHILADELPHIA -- Biofield Corp. (OTC Bulletin Board:BZET.PK), announced today that an initial order of 10 Biofield Breast Diagnostic System (BDS) devices and 20 cases of Biofield sensors were delivered to the new joint venture (JV) company in the Philippines which will distribute the BDS in the Philippines, Indonesia, and Malaysia. The order was delivered in time for a major breast cancer symposium which will take place in Manila on October 24, which will showcase the BDS, and which will be attended by approximately 200 people, including 100 of the top hospital and medical institutions in the Philippines and leading representatives from the Philippines, China and India. The BDS will be presented at the Symposium by Dr. Mark Faupel, inventor of the BDS, and Dr. Ronald Hart, an international health care policy expert from the U.S., as well as by leading doctors in the Philippines, who will present the significant results of Biofield's successful clinical trial in the Philippines.

The new JV, The MacKay-Eastern Medical Group, is a partnership between the MacKay Group Limited (MKG) and Eastern Petroleum Corporation (EPC), one of the leading businesses and petroleum companies in the Philippines, led by its Chairman, Fernando Martinez. 60% of the JV will be owned by EPC with MKG owning 40%. The new JV will undertake all responsibility and expense to, among other things, distribute, market, secure any regulatory approvals, and clinically and otherwise develop the BDS and related technologies, such the SpectRx, Inc. cervical cancer detection system in the Philippines, Indonesia, and Malaysia. According to the U.N., the Philippines, Indonesia, and Malaysia (some of the most populated countries in the world) together have approximately 35 million women ages 40-70. According to the International Agency for Research on Cancer, those countries' breast cancer incidence rates (46.6, 26.1, and 30.8 per 100,000 respectively) are among the highest in Asia.

Further details will be released after the October 24th event, including on Biofield's and/or MKG's website.

Biofield also announced that it filed its Form 10-KSB for year ending December 31, 2006. Now that its annual report is completed, it is proceeding to finalize and file its remaining quarterly reports.

About Biofield Corp.

Biofield Corp., a medical technology company, engages in the development and provision of non-invasive diagnostic medical devices to assist in detecting breast cancer. It offers Biofield Diagnostic System, a breast cancer diagnostic device, which employs single-use sensors to measure and analyze changes in cellular electrical charge distributions associated with the development of epithelial cancers, such as breast, ovaries, skin, prostate, and colon cancers. The company's device is intended for palpable breast lesions, in women under 55 years of age. For more information, go to http://www.biofield.com.

About MacKay Group ...